Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exopolysaccharide from Levilactobacillus brevis M-10
- Development stage
- Preclinical
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Exopolysaccharide (EPS) from *Levilactobacillus brevis* M-10 is a high-molecular-weight polysaccharide secreted by the probiotic bacterium *L. brevis* strain M-10. This EPS has demonstrated significant postbiotic properties, including antioxidant activity and α-glucosidase inhibitory effects in vitro[1][4]. The antioxidant activities are evidenced by radical-scavenging assays (such as DPPH and ABTS), while the α-glucosidase inhibition suggests potential for modulating carbohydrate metabolism and possibly supporting glycemic control[1]. Kinetic studies indicate that the inhibition of α-glucosidase is competitive in nature[1]. As a postbiotic, this EPS may contribute to health benefits associated with probiotic use without requiring live bacteria, making it a promising candidate for functional food or nutraceutical applications[4].
- Other names
- EPS from Levilactobacillus brevis M-10EPS from L. brevis M-10exopolysaccharide of L. brevis M-10
02
Targets
Sucrase-Isomaltase
Beyond the preview
Go deeper on exopolysaccharide from Levilactobacillus brevis M-10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exopolysaccharide from Levilactobacillus brevis M-10.